The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension.
The efficacy and safety of various doses of losartan potassium , a specific and selective angiotensin II receptor antagonist , were compared with those of placebo and enalapril maleate 20 mg in patients with mild to moderate essential hypertension in a r and omized , double-blind , parallel study . We r and omly allocated 576 patients at the end of a 4-week placebo baseline period to 8 weeks of once-daily double-blind treatment with losartan potassium 10 , 25 , 50 , 100 , or 150 mg , enalapril maleate 20 mg , or placebo . After 8 weeks of treatment , mean reductions from baseline in supine systolic/diastolic pressure 24 hours after dosing ( trough ) for losartan potassium 10 , 25 , 50 , 100 , and 150 mg , enalapril maleate 20 mg , and placebo were 7.6/7.9 , 7.8/6.8 , 13.0/10.1 , 8.9/9.9 , 10.5/9.7 , 14.7/11.2 , and 3.8/5.6 mm Hg , respectively . Compared with mean changes in supine diastolic pressure in the placebo group , losartan potassium 50 to 150 mg and enalapril maleate 20 mg produced clinical ly important and statistically significant reductions ( P < or = .01 ) in blood pressure . At 24 hours after dosing , the blood pressure changes obtained with losartan potassium 50 mg were essentially identical to those obtained with enalapril maleate 20 mg . While there was a dose-related effect with losartan potassium from 10 to 50 mg at peak ( 6 hours after dosing ) , doses of 10 and 25 mg were not consistently different from placebo 24 hours after dosing . To assess the once-daily effect of losartan potassium , trough-to-peak ratios of the mean changes in supine diastolic pressure after 8 weeks of treatment were calculated . ( ABSTRACT TRUNCATED AT 250 WORDS
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .